Oxford Ledge
Search
No licensed closing price on file for CAI. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Caris Life Sciences, Inc. (NASDAQ: CAI) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 11:10 UTC.
Caris is an AI-driven precision medicine company that develops molecular profiling solutions primarily for oncology care. The company uses next-generation sequencing, artificial intelligence, and machine learning to analyze tissue and blood samples, generating what it describes as one of the largest multi-modal clinico-genomic datasets in the field. Its Molecular Intelligence product portfolio includes tissue-based and blood-based profiling platforms that serve clinical, academic, and biopharma customers.
Summarized from Caris Life Sciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
| Valuation | |
| EPS (TTM) | $8.32 |
| Return on equity | -11.79% |
| Debt/equity | 0.66 |
Caris is an AI-driven precision medicine company that develops molecular profiling solutions primarily for oncology care.
Caris Life Sciences, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-05. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 11:10 UTC. This page is also available as JSON at /api/data?ticker=CAI and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for CAI and 5,000+ tickers.
Create a free account — keep CAIGET /api/data?ticker=CAI
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt